Blood Cells, Molecules and Diseases


Publication Venue For

  • Metabolic syndrome among adults living with sickle cell disease.  74:25-29. 2019
  • New insights provided by a comparison of impaired deformability with erythrocyte oxidative stress for sickle cell disease.  52:230-235. 2014
  • Tumor necrosis factor-alpha promoter variants and iron phenotypes in 785 Hemochromatosis and Iron Overload Screening (HEIRS) Study participants.  44:252-256. 2010
  • Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.  43:119-128. 2009
  • Post-translational modifications of Runx1 regulate its activity in the cell.  43:30-34. 2009
  • A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy.  42:155-158. 2009
  • Heme degradation and oxidative stress in murine models for hemoglobinopathies: Thalassemia, sickle cell disease and hemoglobin C disease.  41:60-66. 2008
  • Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy.  37:100-106. 2006
  • Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: A role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation.  32:182-190. 2004
  • Intranuclear organization of RUNX transcriptional regulatory machinery in biological control of skeletogenesis and cancer.  30:170-176. 2003
  • Late effects among survivors of leukemia during childhood and adolescence.  31:84-92. 2003
  • The ETO domain is necessary for the developmental abnormalities associated with AML1-ETO expression in the hematopoietic stem cell compartment in vivo.  30:201-206. 2003
  • Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes.  27:610-624. 2001
  • International Standard Serial Number (issn)

  • 1079-9796
  • Electronic International Standard Serial Number (eissn)

  • 1096-0961